FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140758096> ?p ?o ?g. }

• W2140758096 abstract "With the aim of developing an effective therapy for heavily pretreated refractory MM outpatients, we evaluated the OPPEBVCAD regimen, a Hodgkin's disease-derived protocol that includes many drugs effective in MM administered in a sequential schedule. Twenty-two pts aged 42-72 years, with symptomatic highly-pretreated refractory (18 cases), or primary resistant MM (four cases. including two pts with plasma cell leukemia-PCL) received this therapy every 28 days (2-4 cycles, followed by a maintenance program). Therapeutic response (Chronic Leukemia-Myeloma Task Force criteria) and performance status (PS) and pain (W.H.O.) were evaluated. All of the pts were evaluable for response. There were 9 (40%) objective responses (OR: stabilization of blood counts and bone lesions, serum calcium normalization, 50% or more reduction in the concentration of serum monoclonal component (MC), 90% reduction in Bence-Jones proteinuria), 8 (36%) partial responses (PR: 25-50% reduction in serum MC), 1 no response or stable disease (NR), and 4 (18%) cases of progressive disease (PD). OR plus PR were 77%. Of the 4 primary resistant tumors (2 PCL and 2 MM), 2 achieved PR, 1 OR (a PCL case) and 1 progressed. Median survival was 15 months for responding pts (OR plus PR) and 4.5 months for non-responders (NR plus PD). PS and pain improved in 15 pts and did not change in 9. The most frequent side effects were cytopenias, with one drug related infective death. The OPPEBVCAD regimen proved to be an effective therapy for refractory relapsing or primary resistant MM: in responders (two-thirds of the pts), survival was prolonged by about 10 months. Its efficacy in anthracycline-treated pts, as well as the feasibility of using it on an outpatient basis without any continuous drug infusions, make this regimen a promising third line salvage therapy." @default.
• W2140758096 created "2016-06-24" @default.
• W2140758096 creator A5029591572 @default.
• W2140758096 creator A5040440696 @default.
• W2140758096 creator A5043716398 @default.
• W2140758096 creator A5061428933 @default.
• W2140758096 creator A5071379560 @default.
• W2140758096 creator A5074659537 @default.
• W2140758096 creator A5083477087 @default.
• W2140758096 date "2000-01-01" @default.
• W2140758096 modified "2023-09-27" @default.
• W2140758096 title "OPP-EBV-CAD Regimen as Salvage Treatment in Advanced Refractory or Resistant Multiple Myeloma" @default.
• W2140758096 cites W1944894251 @default.
• W2140758096 cites W1969997066 @default.
• W2140758096 cites W1972264308 @default.
• W2140758096 cites W1997804547 @default.
• W2140758096 cites W2000538996 @default.
• W2140758096 cites W2005719111 @default.
• W2140758096 cites W2006909493 @default.
• W2140758096 cites W2022413505 @default.
• W2140758096 cites W2035768145 @default.
• W2140758096 cites W2038380594 @default.
• W2140758096 cites W2040081814 @default.
• W2140758096 cites W2040903318 @default.
• W2140758096 cites W2049420835 @default.
• W2140758096 cites W2055565316 @default.
• W2140758096 cites W2073139525 @default.
• W2140758096 cites W2089984711 @default.
• W2140758096 cites W2090770451 @default.
• W2140758096 cites W2095265892 @default.
• W2140758096 cites W2156537551 @default.
• W2140758096 cites W2157409566 @default.
• W2140758096 cites W2163549274 @default.
• W2140758096 cites W2167805334 @default.
• W2140758096 cites W2301776058 @default.
• W2140758096 cites W4244712501 @default.
• W2140758096 cites W4252605815 @default.
• W2140758096 cites W98986799 @default.
• W2140758096 doi "https://doi.org/10.3109/10428190009054884" @default.
• W2140758096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11426632" @default.
• W2140758096 hasPublicationYear "2000" @default.
• W2140758096 type Work @default.
• W2140758096 sameAs 2140758096 @default.
• W2140758096 citedByCount "1" @default.
• W2140758096 crossrefType "journal-article" @default.
• W2140758096 hasAuthorship W2140758096A5029591572 @default.
• W2140758096 hasAuthorship W2140758096A5040440696 @default.
• W2140758096 hasAuthorship W2140758096A5043716398 @default.
• W2140758096 hasAuthorship W2140758096A5061428933 @default.
• W2140758096 hasAuthorship W2140758096A5071379560 @default.
• W2140758096 hasAuthorship W2140758096A5074659537 @default.
• W2140758096 hasAuthorship W2140758096A5083477087 @default.
• W2140758096 hasConcept C121332964 @default.
• W2140758096 hasConcept C126322002 @default.
• W2140758096 hasConcept C141071460 @default.
• W2140758096 hasConcept C142424586 @default.
• W2140758096 hasConcept C2776364478 @default.
• W2140758096 hasConcept C2776694085 @default.
• W2140758096 hasConcept C2778822529 @default.
• W2140758096 hasConcept C2779338263 @default.
• W2140758096 hasConcept C2780653079 @default.
• W2140758096 hasConcept C2780775027 @default.
• W2140758096 hasConcept C2781413609 @default.
• W2140758096 hasConcept C71924100 @default.
• W2140758096 hasConcept C87355193 @default.
• W2140758096 hasConcept C90924648 @default.
• W2140758096 hasConceptScore W2140758096C121332964 @default.
• W2140758096 hasConceptScore W2140758096C126322002 @default.
• W2140758096 hasConceptScore W2140758096C141071460 @default.
• W2140758096 hasConceptScore W2140758096C142424586 @default.
• W2140758096 hasConceptScore W2140758096C2776364478 @default.
• W2140758096 hasConceptScore W2140758096C2776694085 @default.
• W2140758096 hasConceptScore W2140758096C2778822529 @default.
• W2140758096 hasConceptScore W2140758096C2779338263 @default.
• W2140758096 hasConceptScore W2140758096C2780653079 @default.
• W2140758096 hasConceptScore W2140758096C2780775027 @default.
• W2140758096 hasConceptScore W2140758096C2781413609 @default.
• W2140758096 hasConceptScore W2140758096C71924100 @default.
• W2140758096 hasConceptScore W2140758096C87355193 @default.
• W2140758096 hasConceptScore W2140758096C90924648 @default.
• W2140758096 hasLocation W21407580961 @default.
• W2140758096 hasLocation W21407580962 @default.
• W2140758096 hasOpenAccess W2140758096 @default.
• W2140758096 hasPrimaryLocation W21407580961 @default.
• W2140758096 hasRelatedWork W124574976 @default.
• W2140758096 hasRelatedWork W1511417912 @default.
• W2140758096 hasRelatedWork W1599228932 @default.
• W2140758096 hasRelatedWork W1817229679 @default.
• W2140758096 hasRelatedWork W1834314364 @default.
• W2140758096 hasRelatedWork W1884938169 @default.
• W2140758096 hasRelatedWork W1979809726 @default.
• W2140758096 hasRelatedWork W1988166471 @default.
• W2140758096 hasRelatedWork W2018555704 @default.
• W2140758096 hasRelatedWork W2028340626 @default.
• W2140758096 hasRelatedWork W2066073173 @default.
• W2140758096 hasRelatedWork W2076026332 @default.
• W2140758096 hasRelatedWork W2092643001 @default.
• W2140758096 hasRelatedWork W2093159499 @default.
• W2140758096 hasRelatedWork W2123955706 @default.
• W2140758096 hasRelatedWork W2147648496 @default.

• next